Sugi Predict

Sugi Predict / Compounds / SCHEMBL309140

SCHEMBL309140

SCHEMBL309140

CCOC(=O)c1cnn2cc(F)cnc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.55
▸ HPGD P15428 4/20 0.55
▸ KDM4E B2RXH2 7/20 0.54
▸ NPC1 O15118 4/20 0.54
▸ RAB9A P51151 4/20 0.54
▸ HSD17B10 Q99714 4/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ GAA P10253 1/20 0.46
▸ TGFBR1 P36897 1/20 0.44
▸ PDE4B Q07343 1/20 0.43
▸ CSNK1D P48730 1/20 0.43
▸ POLB P06746 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ NFKB2 Q00653 1/20 0.43
▸ RELA Q04206 1/20 0.43
▸ LMNA P02545 2/20 0.42
▸ PDE2A O00408 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17781274 0.86 KDM4E (0.57) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL23728550 0.84 ALDH1A1 (0.56) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL23728526 0.84 ALDH1A1 (0.56) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL10071025 0.84 LMNA (0.44) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL23728472 0.83 ALDH1A1 (0.55) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL14033767 0.83 ALDH1A1 (0.55) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL23728470 0.82 ALDH1A1 (0.54) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL23728467 0.81 ALDH1A1 (0.53) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL14033079 0.81 ALDH1A1 (0.53) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL23728603 0.81 KDM4E (0.55) ALDH1A1HPGDKDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113773335-B Compound serving as protein kinase inhibitor and preparation method and application thereof 成都海博为药业有限公司 2024-12-03 — — CN disclosed
CN-112979654-B Heteroaryl fused ring compounds, preparation method and application thereof 赛诺哈勃药业（成都）有限公司 2024-03-19 — — CN disclosed
US-11649241-B2 Pyrazolochlorophenyl compounds, compositions and methods of use thereof GENENTECH, INC. (US) 2023-05-16 — — US disclosed
US-20220332718-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS GENENTECH, INC. (US) 2022-10-20 — — US disclosed
EP-3596072-B1 PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF HOFFMANN LA ROCHE (CH) 2022-06-22 — — EP disclosed
CN-110494434-B Pyrazolophenyl compounds, compositions thereof, and methods of use thereof 豪夫迈·罗氏有限公司 2022-05-24 — — CN disclosed
CN-108473498-B Pyrazolo [1,5a ] pyrimidine derivatives as IRAK4 modulators 豪夫迈·罗氏有限公司 2021-11-02 — — CN disclosed
US-20210179626-A1 PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-06-17 — — US disclosed
US-10988478-B1 Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators GENENTECH, INC. (US) 2021-04-27 — — US disclosed
US-10988478-B1 Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators GENENTECH, INC. (US) 2021-04-27 — — US disclosed
EP-2313413-B1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES CONVERGENCE PHARMACEUTICALS (GB) 2012-05-16 — — EP disclosed
US-8093249-B2 Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives Convergence Pharmaceuticals Limited (GB) 2012-01-10 — — US disclosed
US-8093249-B2 Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives Convergence Pharmaceuticals Limited (GB) 2012-01-10 — — US disclosed
US-8093249-B2 Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives Convergence Pharmaceuticals Limited (GB) 2012-01-10 — — US disclosed
EP-2313413-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES Convergence Pharmaceuticals Limited (GB) 2011-04-27 — — EP disclosed
US-20100016330-A1 Novel Derivatives Convergence Pharmaceuticals Limited (GB) 2010-01-21 — — US disclosed
US-20100016330-A1 Novel Derivatives Convergence Pharmaceuticals Limited (GB) 2010-01-21 — — US disclosed
US-20100016330-A1 Novel Derivatives Convergence Pharmaceuticals Limited (GB) 2010-01-21 — — US disclosed
WO-2010007074-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2010-01-21 — — WO disclosed
WO-2010007074-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2010-01-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210179626-A1 PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF JAK1, JAK2, JAK3 ALDH1A1 1102/4885HPGD 1635/4885KDM4E 834/4885
US-20100016330-A1 Novel Derivatives CACNB2, CACNA1B, CACNA1D ALDH1A1 3984/4885HPGD 2351/4885KDM4E 3426/4885
US-11649241-B2 Pyrazolochlorophenyl compounds, compositions and methods of use thereof JAK1, JAK2, JAK3 ALDH1A1 1102/4885HPGD 1635/4885KDM4E 834/4885
US-20220332718-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS IRAK1, IRAK4, IRAK2 ALDH1A1 1115/4885HPGD 3802/4885KDM4E 662/4885
US-10988478-B1 Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators IRAK1, IRAK4, IRAK2 ALDH1A1 1146/4885HPGD 3701/4885KDM4E 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.